Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 8/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18249612 | 0.90 | SLC6A2 (0.44) | SLC6A3SLC6A4SLC6A2CES2CES1 | |
| Oxalic Acid SCHEMBL20164082 | 0.85 | SLC6A4 (0.33) | SLC6A3SLC6A4SLC6A2CES2CES1 | |
| Oxalic Acid SCHEMBL28483412 | 0.85 | SLC6A4 (0.33) | SLC6A3SLC6A4SLC6A2CES2CES1 | |
| Oxalic Acid SCHEMBL28483532 | 0.81 | SLC6A4 (0.35) | SLC6A3SLC6A4SLC6A2CHRNB2CHRNA4 | |
| Oxalic Acid SCHEMBL18249611 | 0.81 | SLC6A4 (0.35) | SLC6A3SLC6A4SLC6A2CHRNB2CHRNA4 | |
| Oxalic Acid SCHEMBL20164103 | 0.75 | CES2 (0.40) | SLC6A3SLC6A4SLC6A2CES2CES1 | |
| Oxalic Acid SCHEMBL28492025 | 0.75 | CES2 (0.40) | SLC6A3SLC6A4SLC6A2CES2CES1 | |
| Oxalic Acid SCHEMBL28482662 | 0.74 | CES2 (0.38) | SLC6A3SLC6A4SLC6A2CES2CES1 | |
| Oxalic Acid SCHEMBL20164097 | 0.74 | CES2 (0.38) | SLC6A3SLC6A4SLC6A2CES2CES1 | |
| SCHEMBL20164094 | 0.74 | CES2 (0.38) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107646031-B | Azetidine derivatives as modulators of cortical catecholaminergic neurotransmission | 综合研究实验室瑞典股份公司 | 2020-11-17 | — | — | CN | disclosed |
| EP-3297987-B1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2019-05-15 | — | — | EP | disclosed |
| US-10287247-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2019-05-14 | — | — | US | disclosed |
| US-20190031606-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2019-01-31 | — | — | US | disclosed |
| US-10087142-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES (SE) | 2018-10-02 | — | — | US | disclosed |
| US-20180141903-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2018-05-24 | — | — | US | disclosed |
| EP-3297987-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | Integrative Research Laboratories Sweden AB (SE) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016185032-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141903-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | SLC18A2, SLC18A1, SLC18A3 | SLC6A4 30/4885SLC6A3 7/4885SLC6A2 4/4885 |
| US-10287247-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | SLC18A2, SLC6A2, SLC18A3 | SLC6A4 13/4885SLC6A3 5/4885SLC6A2 2/4885 |
| US-10087142-B2 | Azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission | SLC18A2, SLC6A2, SLC18A1 | SLC6A4 31/4885SLC6A3 5/4885SLC6A2 2/4885 |
| US-20190031606-A1 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATHECOLAMINERGIC NEUROTRANSMISSION | SLC18A2, SLC6A2, SLC18A3 | SLC6A4 8/4885SLC6A3 4/4885SLC6A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.